Community Research and Development Information Service - CORDIS

H2020

ProEmpower Report Summary

Project ID: 727409
Funded under: H2020-EU.3.1.4.

Periodic Reporting for period 1 - ProEmpower (Procuring innovative ICT for patient empowerment and self-management for type 2 diabetes mellitus)

Reporting period: 2016-10-01 to 2017-07-31

Summary of the context and overall objectives of the project

Diabetes mellitus is a chronic, life-long, rising and very broad disease accompanied by many co-morbid conditions, complications and stages. Medical services for diabetes are available in all public and private sectors of healthcare systems, numerous medications have been developed, most importantly the body hormone insulin, and commercial support services back care providers’ efforts with products adapted to the needs of those living with the disease. Diabetes is also intensely researched and subject to health reporting in many industrialised countries, the majority of which also have national diabetes guidelines in place. Diabetes represents worldwide nevertheless an increasing burden on the cost of health care systems and the care offered is far from perfect. Usual care in most regions of Europe reacts to incidents rather than actively managing care. Diabetes care is also far from being fully integrated and further set back by the lack of interoperability across healthcare systems. The quality of many commercial internet-based services remains an issue and the focus on diabetes as a disease often fails to properly address social aspects in patients’ lives, such as retirement issues and the compatibility of diabetes and working.
ProEmpower is a pre–commercial procurement (PCP) project to buy R&D (research and development) services to improve the treatment and self-management of diabetes type 2 patients using a Personalised Diabetes Management Solution. The project brings together procurers from four regions in Europe. The regional health procurement bodies are supported by health provider organisations and consultancies.
The solutions are expected to improve the detection of type II diabetes and the treatment through person-centred and personalised care. This includes addressing the problems of the patients, improving their knowledge of diabetes, supporting them in communicating their treatment preference to physicians and facilitating a healthy lifestyle.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The project started by updating the unmet needs and defining a common vision across the procurers. The consortium defined together common procurement requirements for an innovative diabetes management solution that will address their needs. The requirements are complemented by use cases and process models to capture the necessary functionality of the solution. The resulting technical specification is included in the tender documents.
ProEmpower organised Open Market Consultation workshops in five different countries, as well as one webinar, to consult the supply side and validate and improve the technical specification, as well as mobilise the supply side to participate in the call for tender. The following consultations have take place: Murcia, Spain (24 May 2017); Lisbon, Portugal (29 May 2017); Ankara, Turkey (31 May 2017); Naples, Italy (6 June 2017); Sofia, Bulgaria (14 June 2017); a webinar on 8 June 2017. The events attracted in total representatives of over 140 companies, confirming that the ProEmpower initiative has successfully made its initial message heard.
The ProEmpower tender documents are currently being evaluated by the European Commission, after which the project will move to the next phase of publishing the call documents.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

ProEmpower aims at providing a comprehensive solution for diabetes management that is fully integrated into the healthcare systems of the procurers and provides benefits to both patients, healthcare professionals and the system as a whole. The project goes beyond state of the art in that it aims to close the fragmentation gap, seeking for a comprehensive, fully integrated and interoperable solution covering the all building blocks of a continuous diabetes management approach. R&D innovation is also expected in the individual building blocks. This includes Integration of different patient data to enable better treatment, comprehensive training using state-of-the-art technologies, learning using IT, use of novel techniques to improve patients’ daily routines (e.g. wearables and other hardware, automatic recognition of patient activity), innovative algorithms for early detection, forecasting daily blood glucose long-term effects using simulations, new ways of communication between patient and doctor, use of a diabetes shared care plan, empowerment through peer and community support, etc.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top